September is Childhood Cancer Awareness Month, a time to recognize the children and families affected by childhood cancers and to emphasize the importance of supporting research on these devastating conditions.
100% of net profits from this collection will be donated to Children's Cancer Therapy Development Institute.
For the fourth year in a row, we partnered with our dear friend Megan Bugg, a 19-year-old superhero who has been battling Stage 4 alveolar rhabdomyosarcoma since she was first diagnosed at age 13, to bring you our 2020 Childhood Cancer Awareness Collection.
Due to the tremendous attention paid to certain types of cancers, most federal and private dollars are not dedicated to effective treatments and cures of childhood cancer. Megan's "More Than Four" is a call for childhood cancer to receive more than just 4% of total research funding.
Shop Now"Itβs a time for all of us to remember that no one deserves cancer, but especially kids donβt deserve cancer. We have to do better by our kids, because our kids deserve far more than 4% of Federal funding for cancer research."
-Megan Bugg
Even during the pandemic, childhood cancer remains the number one cause of death by disease for children in the U.S. and around the world. Shop our 2020 collection and go gold all month long.
Perfect for anything from smoothies to tea and coffee. The perfect way to show you care on a daily basis. You'll use your tumbler with pride.
100% of net profits from every style in this collection goes to Children's Cancer Therapy Development Institute.
We've partnered with Luca + Danni to create a bracelet to raise awareness and fundraise to help prevent childhood cancer. Show your support in silver or brass!
Be a super supporter and get all of the Childhood Cancer pieces in one bundle.
In partnership with Luca + Danni, the Childhood Cancer Awareness Bracelet makes a perfect way to show your support and give back at the same time.
100% of net profits from this collection will go to Children's Cancer Therapy Development Institute.
Donations will go specifically to fund preclinical testing for a drug that has shown tremendous promise in the CC-TDI labs as a potential treatment that could restore chemotherapy sensitivity and thereby improve outcomes for rhabdomyosarcoma patients.